More potent than SN38 and Dxd, but less toxic than commonly used high-potent toxin, such as auristatin and emtansine

Wide tumoricidal spectrum, highly effective in multi-drug resistant models

Superb by-stander effect

Highly efficient cystine-based chemical conjugation

Great linker-payload stability and tumor-specific cleavage mechanism

Outstanding conjugate hydrophilicity

Enhanced mAb-linker stability with minimized de-conjugation

Systematically studies elucidated the mechanism of actions of the EZWi-Fit® at the molecular, cellular, and in vivo levels, including linker cleavage, anti-multi-drug resistance, payload bystander effect, and in vivo efficacy in low-expressing target tumor models. Study  results provide strong and convincing evidences that EZWi-Fit® platform technology has superior competitive advantages than other benchmarking ADC platforms in development

Affluent in vitro and in vivo studies of ADCs targeting multiple targets, developed based on EZWi-Fit® platform, demonstrate great efficacy on different tumor models, including CDXs and PDXs. The GLP-compliant repeated-dosing NHP safety studies of several ADCs proof improved tolerability comparing with other benchmarking ADC platforms

Escugen has successfully licensed-out the EZWi-Fit® technology, as well as a FIC ADC pipeline, to multiple domestic and international biotech companies, empowering more ADC drug development